Last reviewed · How we verify
Chixiangshen Tongxin granules
Chixiangshen Tongxin granules, marketed by Liaoning University of Traditional Chinese Medicine, holds a niche position in the traditional Chinese medicine segment. The drug's key strength lies in its unique composition, protected by a patent expiring in 2028. The primary risk is the lack of clear primary indication and revenue data, which may limit its market expansion and investor confidence.
At a glance
| Generic name | Chixiangshen Tongxin granules |
|---|---|
| Also known as | Chixiangshen Tongxin granules from Jiangyin Tianjiang Pharmaceutical Co., Ltd |
| Sponsor | Liaoning University of Traditional Chinese Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: